Cargando…

Author Correction: Hyperprogression under Immune Checkpoint Inhibitor: a potential role for germinal immunogenetics

Detalles Bibliográficos
Autores principales:	Refae, Sadal, Gal, Jocelyn, Brest, Patrick, Giacchero, Damien, Borchiellini, Delphine, Ebran, Nathalie, Peyrade, Frederic, Guigay, Joël, Milano, Gérard, Saada-Bouzid, Esma
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Author Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289853/ https://www.ncbi.nlm.nih.gov/pubmed/32528006 http://dx.doi.org/10.1038/s41598-020-66841-w

Ejemplares similares

Hyperprogression under Immune Checkpoint Inhibitor: a potential role for germinal immunogenetics
por: Refae, Sadal, et al.
Publicado: (2020)

Host Polymorphisms May Impact SARS-CoV-2 Infectivity
por: Brest, Patrick, et al.
Publicado: (2020)

Exploration of the immunogenetic landscape of hyperprogressive disease after combined immunotherapy in cancer patients
por: Gong, Caifeng, et al.
Publicado: (2023)

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
por: Adashek, Jacob J., et al.
Publicado: (2019)

Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors
por: Kasparian, Saro, et al.
Publicado: (2020)

KIR/HLA immunogenetic background influences the evolution of hepatocellular carcinoma
por: Cariani, Elisabetta, et al.
Publicado: (2013)

Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors
por: Shen, Pan, et al.
Publicado: (2021)

Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses
por: Zang, Hongjing, et al.
Publicado: (2020)

Abigene, a Prospective, Multicentric Study of Abiraterone Acetate Pharmacogenetics in Metastatic Castration-Resistant Prostate Cancer †
por: Ferrero, Jean-Marc, et al.
Publicado: (2023)

Hyperprogression in Pediatric Melanoma Metastatic to the Breast Treated with a Checkpoint Inhibitor
por: Bernal Vaca, Laura, et al.
Publicado: (2019)

How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?
por: Denis, Morgane, et al.
Publicado: (2020)

Immune Cells in Hyperprogressive Disease under Immune Checkpoint-Based Immunotherapy
por: Wei, Zhanqi, et al.
Publicado: (2022)

Host genetic variability and determinants of severe COVID-19
por: Brest, Patrick, et al.
Publicado: (2023)

VEGF-Related Germinal Polymorphisms May Identify a Subgroup of Breast Cancer Patients with Favorable Outcome under Bevacizumab-Based Therapy—A Message from COMET, a French Unicancer Multicentric Study
por: Gal, Jocelyn, et al.
Publicado: (2020)

Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer
por: Soria, Francesco, et al.
Publicado: (2018)

The good, the bad, and the ugly: hyperprogression in cancer patients following immune checkpoint therapy
por: Sabio, Erich, et al.
Publicado: (2019)

Hyperprogressive Disease In Cervical Small Cell Carcinoma Treated By Immune Checkpoint Inhibitor
por: Xu, Zihan, et al.
Publicado: (2019)

Hyperprogressive disease rarely occurs during checkpoint inhibitor treatment for advanced melanoma
por: Schuiveling, M., et al.
Publicado: (2020)

Hyperprogressive Disease in Malignant Carcinoma With Immune Checkpoint Inhibitor Use: A Review
por: Liu, Xiaojun, et al.
Publicado: (2022)

Hyperprogression under Immunotherapy
por: Frelaut, Maxime, et al.
Publicado: (2019)

Hyperprogression after immunotherapy
por: Abbas, Waseem, et al.
Publicado: (2019)

Immunogenetics special issue 2023: Immunogenetics of infectious disease
por: Norman, Paul J.
Publicado: (2023)

Redefine Hyperprogressive Disease During Treatment With Immune-Checkpoint Inhibitors in Patients With Gastrointestinal Cancer
por: Wang, Zhenghang, et al.
Publicado: (2021)

Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis
por: Kim, Jong Yeob, et al.
Publicado: (2019)

BASIC IMMUNOGENETICS
Publicado: (1973)

Journal of Immunogenetics
por: Harris, R.
Publicado: (1974)

Hodgkin’s Lymphoma in Older Patients: an Orphan Disease?
por: Thyss, Antoine, et al.
Publicado: (2014)

Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don’t) know
por: Camelliti, Simone, et al.
Publicado: (2020)

A nomogram for predicting hyperprogressive disease after immune checkpoint inhibitor treatment in lung cancer
por: Cao, Shuhui, et al.
Publicado: (2022)

PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors
por: Gabryś, H. S., et al.
Publicado: (2022)

Hyperprogression after Immunotherapy: Nivolumab. Analysis of Imaging Findings Associated with Hyperprogression and Tumor Growth Kinetics
por: Singla, Rishu, et al.
Publicado: (2021)

Immunogenetics of Tissue Transplantation
por: Mitchell, Malcolm S.
Publicado: (1970)

Immunogenetics of Hashimoto's thyroiditis
por: Chistiakov, Dimitry A
Publicado: (2005)

The Immunogenetics of Autoimmune Cholestasis
por: Trivedi, Palak J., et al.
Publicado: (2016)

The Immunogenetic Conundrum of Preeclampsia
por: Lokki, A. Inkeri, et al.
Publicado: (2018)

Psoriasis: An Immunogenetic Perspective
por: Kocaaga, Ayca, et al.
Publicado: (2022)

The immunogenetics of COVID-19
por: Srivastava, Anshika, et al.
Publicado: (2022)

Prediction model for hyperprogressive disease in non‐small cell lung cancer treated with immune checkpoint inhibitors
por: Choi, Yong Jun, et al.
Publicado: (2020)

Hyperprogressive Disease (HPD) in Solid Tumours Receiving Immune Checkpoint Inhibitors in a Real-World Setting
por: Kanjanapan, Yada, et al.
Publicado: (2023)

Beyond EGFR Targeting in SCCHN: Angiogenesis, PI3K, and Other Molecular Targets
por: Saada-Bouzid, Esma, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_06qruhiuuett6b561fet6addhe